Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVR 3-778 in HBeAg-Positive Chronic Hepatitis B
NCT02401737Phase 1Completed
- Sponsor
- Novira Therapeutics
- Start
- Jan 2015
- Primary completion
- May 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of AL-3778 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Novira Therapeutics. Primary endpoint: Decline of serum HBV-DNA at 28 days. Started Jan 2015; status: completed.
02
Drugs
AL-3778
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02401737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02401737.